poisar

Stocks · News reference

EyePoint Pharmaceuticals Reports Third Quarter 2026 Financial Results

Fiscal.ai

EyePoint, Inc. announced its financial results for the third quarter ended September 30, 2026, and provided updates on its clinical development programs.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Fiscal.ai

    Class Action Lawsuit Filed Against EyePoint, Inc.

    Pomerantz LLP has announced the filing of a class action lawsuit against EyePoint, Inc. and certain officers regarding alleged misleading statements about the company's business and the efficacy of its product candidate, DURAVYU.

  2. BenzingaEarnings Transcripts

    EyePoint Pharmaceuticals Q3 2026 Earnings Call Transcript

    EyePoint Pharmaceuticals (NASDAQ:EYPT) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by

  3. SEC EDGARSEC EDGAR

    8-K filing — EyePoint, Inc. (EYPT)

    Filed: 2026-11-12 AccNo: 0001193125-26-456889 Size: 587 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits